Rainier Acquisition Corp
RNAQ · Biotech
NO ACTION REQUIRED
Nothing required today
No redemption election is on file for this SPAC. A date appears here the day one is filed.
Cash per share
Held for each public share, as last filed.
Last close
Daily close
No price history on file yet — daily closes accumulate from the market data feed.
SpacBrain’s read
Floor not confirmed
No redemption window has closed — but no dated redemption election is on file for this name either, so we cannot show you a date to act by.
What we do have: no window has closed, and no company deadline is on file either. The full chain of evidence is under Evidence.
In plain terms
- What it is
- A SPAC from Ravenna 7 LLC, listed in August 2026.
- What it's doing now
- It is still looking: no purchase has been announced, and no deadline for agreeing one is on file with us.
- What you should know
- We have no filed date on which you could claim the cash back, so we cannot tell you a day to act by. That is a gap in the public record, not a statement that the right has gone.
At a glance
- Where it stands
- Searching
- Merging with
- No target announced — still searching.
- Industry
- Biotech
- What it set out to buy: Biotech
- Deal value
- not stated in the filings we hold
- Price vs cash floor
- no live price on file
- Cash left in trust
- not yet extracted into a snapshot — the filings below may state it
- IPO
- 27 August 2026
- size not on file · 100.0% of each $10 unit into trust
- Headquarters
- 1 PENN PLAZA, 48TH FLOOR, NEW YORK, NY, 10119
- registered in the Cayman Islands
- Lead underwriter
- Chardan Capital Markets, LLC
- Key officers
- GROSSMAN JONAS (Director) · Lam Wing C. (Director) · Amusa Gbolahan (Chief Executive Officer)
- Listed securities
- RNAQ common · RNAQU unit $10.17
As last filed — the filing date is not recorded.
Nothing dated is on file. That is an absence in our record, not a statement that nothing is coming.
Yield to redemption
No dated redemption window on file — no yield to compute.
No price on file — nothing to buy at. An unsourced date would make the yield look filed when it is not.
What is protecting this price
The reasoning behind the verdict above, in the order the filings establish it.
- No dated redemption election is on file for this name. That is an absence in the record, not proof that the right has gone — but it does mean this page cannot tell you a day to act by.
- Cash held in trust is $10.00 per share as last filed. That is the figure a redemption pays out at, plus whatever interest the trust earns between the filing and the window.
What has happened, and what is coming
1 dated milestoneEvery dated step from the day it listed to the next date you may have to act on. Where you have to do something, the day your broker needs the instruction is marked too.
- 27 August 2026IPOpassed
IPO size not on file
The score
deterministic, from filed fieldsRNAQ is not in the scored universe, so no score is shown. A withheld score is a fact about the record, not a verdict about the company.
The score is only published for names that carry both a price and a filed cash-per-share figure — 292 of the tracked fleet today. The rest keep an empty dial rather than a modelled one, and fill in by themselves as the fields land.
The company
from SEC filingsRead the full profile
A planned $75 million SPAC from Ravenna 7 LLC that filed its first prospectus with the SEC in August 2026 — 7.5 million units at $10, aimed at companies that apply biology to human health: therapeutics, diagnostics, genomics, precision medicine, life-science tools and related fields. Not yet listed; no ticker or target.
Material findings
from the full read of every filingEvery document this company files gets read whole — body and exhibits. These are the ones the read flagged as material, newest first, each citing its filing.
Investors should note that the full trust value is now established at $86,250,000, setting the baseline for redemption calculations and potential business combination targets, while the sponsor's additional capital commitment signals confidence in the deal structure.
This filing provides investors with the complete set of terms for the SPAC's IPO, including redemption mechanics, sponsor compensation and resulting dilution, conflicts of interest (Chardan acts as both underwriter and has an economic interest in the sponsor), the composition and experience of the management team, and the financial condition of the SPAC (working capital deficit of $80,846 as of June 30, 2026, with going concern uncertainty). It also details the 24-month timeframe, the absence of a maximum redemption threshold, and the 15% limitation on redemption by any single beneficial owner. This is the foundational document for evaluating the investment.
Sets the structural and timeline terms for investors: $10.00 per share trust initially, 24-month completion window, life sciences focus, sponsor with Chardan affiliation, substantial dilution from founder shares, and redemption mechanics with a 15% cap on redemptions if shareholder vote is used.
Filings
live EDGAR feedEverything this company has filed with the SEC recently, newest first, each with a plain summary of what changed and why it matters.
What changed: Rainier Acquisition Corp (RNAQ) reported the closing of its $10.00 per unit IPO and over-allotment option on September 2, 2026, generating $86,250,000 in gross proceeds placed in a trust account. The filing details the simultaneous private placement of 200,000 units to Sponsor Ravenna 7 LLC at $10.00 per unit and includes an audited balance sheet as of August 28, 2026. Why it matters: Investors should note that the full trust value is now established at $86,250,000, setting the baseline for redemption calculations and potential business combination targets, while the sponsor's additional capital commitment signals confidence in the deal structure.
What changed: Rainier Acquisition Corp (CIK 2147219) filed an 8-K on August 28, 2026, reporting the consummation of its initial public offering (IPO) on that date. The Company sold 7,500,000 Units at $10.00 per Unit, generating $75,000,000 in gross proceeds. Each Unit consists of one Class A ordinary share and one-quarter of a redeemable warrant exercisable at $11.50. Simultaneously, the Sponsor, Ravenna 7 LLC, purchased 194,375 Private Placement Units at $10.00 per unit for $1,943,750. A total of $75,000,000 was placed into a U.S.-based trust account maintained by Continental Stock Transfer & Trust Company. The filing also details the appointment of Wing C. Lam and Chidozie Ugwumba to the Board of Directors, the adoption of the Second Amended and Restated Memorandum and Articles of Association, and the establishment of Audit, Compensation, and Nominating committees with specified independent directors. Why it matters: This filing confirms the successful completion of the SPAC's capital raise, establishing the initial trust value of $10 per public share ($75,000,000 total). It defines the redemption mechanics: shareholders may redeem shares if the Company does not complete a business combination within 24 months from the IPO closing (August 28, 2026), or upon certain amendments to the charter. The document sets the timeline for the initial business combination deadline as August 28, 2028, unless extended. It also identifies the key governance structure and sponsor commitments, including the Letter Agreement requiring the Sponsor and directors to vote in favor of the initial business combination or facilitate liquidation if no deal is completed.
Show the other 10 filings
What changed: Registration statement on Form S-1 for an initial public offering of 7,500,000 units (each unit consisting of one Class A ordinary share and one-quarter of a redeemable warrant) at $10.00 per unit, with an over-allotment option of 1,125,000 additional units, by Rainier Acquisition Corporation, a blank check company focused on life sciences. This is the initial filing of the S-1 registration statement, marking the first public disclosure of the SPAC's IPO terms. Key elements include: $75,000,000 trust account ($10.00 per unit), 24-month deadline to complete a business combination, sponsor Ravenna 7 LLC (affiliated with underwriter Chardan Capital Markets), 2,156,250 founder shares purchased for $25,000, private placement of 194,375 units at $10.00 each, target focus on life sciences companies, and various agreements including warrant agreement, registration rights, and indemnification. Why it matters: This filing provides investors with the complete set of terms for the SPAC's IPO, including redemption mechanics, sponsor compensation and resulting dilution, conflicts of interest (Chardan acts as both underwriter and has an economic interest in the sponsor), the composition and experience of the management team, and the financial condition of the SPAC (working capital deficit of $80,846 as of June 30, 2026, with going concern uncertainty). It also details the 24-month timeframe, the absence of a maximum redemption threshold, and the 15% limitation on redemption by any single beneficial owner. This is the foundational document for evaluating the investment.
The sponsor
The people who set this company up, what they have done before, and the advisers around the deal.
At-risk capital: $2M — 194,375 private placement units, bought at the IPO and worthless if the company liquidates. This is what the sponsor itself loses if no deal closes. per the prospectus (S-1 0001104659-26-092088)
Ravenna 7 LLCnamed as sponsor in this SPAC’s filings — but with no researched track record behind it yet.
A missing score, not a score of zero — why
A Sponsor Score is only published once the sponsor’s prior vehicles have been verified on EDGAR and their post-close outcomes priced. That record does not exist for this sponsor yet, so no number and no tier is shown. That is a missing score, not a score of zero — and not a neutral 50 either.
Coverage so far: 301 of 1282 tracked SPACs (23%) are attached to a scored sponsor. This card fills in by itself as the research lands.
Deal team — named in the prospectus
- Chardan Capital Markets, LLCLead-left
Read from this SPAC’s own prospectus; the arrow opens the filing. Firms link to their full mandate record.
The record
The reference detail — how the shares were structured at listing, how thinly they trade, and where the company is registered.
Show the reference detail
Unit structure
Unit: U = S + W/4 · 100.0% of the $10 unit
from S-1 0001104659-26-092088
as of 10 September 2026
Trading & liquidity
Company profile
Directors & officers
- GROSSMAN JONASDirector
- Lam Wing C.Director
- Amusa GbolahanChief Executive Officer
- Barudin GuyChief Financial Officer
- Manke IsaacDirector
- Ugwumba ChidozieDirector
- Zweiman Ari10% owner
Sources on file
harvested pages, kept in fullEvery public page we have read about this company, stored in full so a source can never go missing.
Show the sources
38 full SEC filing texts archived — searchable, never lost.
- Vault note — RNAQ (Rainier Acquisition Corp)
vault-note · /vault/tickers/RNAQ
- Vault note — CIK2147219 (Rainier Acquisition Corp)
vault-note · /vault/tickers/CIK2147219
In plain English
tap a term to open itEvery piece of jargon this page could have used, and what it actually means.
Open the plain-English guide
No floor / floorlessthe cash guarantee is gone — the price is unprotected
A SPAC's downside protection is not the cash in trust; it is your right to demand that cash. Once the redemption window closes, the cash stays with the company and the share can trade anywhere.
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Broker action datethe day your broker needs the instruction — earlier than the official date
Brokers batch redemption instructions to the transfer agent, so the practical cutoff is roughly two business days before the published deadline. This is the date that actually costs people the floor.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Trust discountbuying below the cash held for you
Only meaningful while a redemption right exists. On a floorless name the same arithmetic is not a discount, it is the market pricing distress, and this product will not call it a yield.
Dilutionhow much of the company new shares take from you
Sponsor promote, PIPE shares, warrants and rights all issue stock that did not pay $10 for it. The headline deal value is before that; the effective value is after.
Pro-forma equitywhat the company is valued at once the deal closes
The combined company's equity value assuming the announced terms and the redemptions that have actually happened.
ARShow much upside you get per unit of downside
SpacBrain's asymmetric-return score. It is deterministic — the same inputs always produce the same number — and it is capped, not zeroed, when the floor is gone.
De-SPACthe day the SPAC becomes the real company
The shares stop being a claim on a pot of cash and start being equity in an operating business. Roughly 80% of recent de-SPACs traded below $10 within a year.
Outside datethe contractual long-stop for closing the deal
A deadline between the SPAC and its target, not between the SPAC and you. It confers no right to cash, which is exactly why it must never be counted as a redemption window.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.
Accreted NAV (estimate)the last filed cash figure, plus the interest it should have earned since
A model, not a filing: last filed value compounded at the 3-month T-bill for the days elapsed. Always shown in italic with the word estimate, and never printed beside a filed number without it.
Ask the brain
from its filingsData provenance & audit trail5 internal entries
Written by SpacBrain’s data agents whenever a figure is captured, corrected or flagged, and kept verbatim so every number on this page can be traced back to the filing that states it. This is a running log, not the current record: an early entry may be superseded by a later correction — the panels above always hold the current values.
registered from S-1 — pre-listing, ticker TBD, VERIFY it is a SPAC
CORRECTION of an automated read. The S-1 beneficial-ownership table for Rainier Acquisition Corp begins a row "…Offering Ravenna 7 LLC (our sponsor)" — "Offering" is the preceding column header, not part of the name. Sponsor is "Ravenna 7 LLC" (acc 0002147219 S-1).
warrantStrike=11.5, warrantCallPrice=16.5, unitSeparationDays=52 from the definitive prospectus (0001104659-26-092088). NOT FILLED: rightShareRatio — no stated candidate
trustPerShare = initial trust per unit as priced (S-1 0001104659-26-092088) — no 10-Q trust reading on file yet
CIK2147219 → RNAQ from SEC submissions